Galenica continues to grow: revenue rises to over CHF 4 billion |
06.02.2026
| from Galenica AG
06.02.2026, Revenue increased by 5.5% to CHF 4,135.6 million. Broad-based growth – all business areas contributed. Strong pharmacy business driven by prescription medicines and dietary supplements. Continuous growth in wholesale. New “Diagnostics” segment contributes 1% to revenue growth. EBIT¹ guidance with an increase of 10–12% confirmed. Dividend expected to be at least at the previous year’s level.
Galenica continues its growth trajectory in 2025. The Group’s revenue increased by 5.5% to CHF 4,135.6 million, reaching the highest level in the company’s history. The revenue increase is broadly supported across all business areas. Galenica was able to further strengthen its position both in the pharmacy and wholesale businesses. In addition, the new business area “Diagnostics” also contributed to revenue growth. Revenue growth was driven in particular by strong demand for prescription medicines, including GLP-1-based weight-loss products, as well as dietary supplements.
Marc Werner, CEO of Galenica, on the revenue figures: “Our broad positioning and the close interlinking within the network give us the necessary stability to continue growing and to help shape healthcare in Switzerland.” With this growth, Galenica clearly meets its stated revenue forecast. In addition, Galenica confirms the increased EBIT outlook announced in connection with the acquisition of Labor Team: for 2025, the Group expects an EBIT¹ increase of 10–12%. Galenica also continues to expect a dividend at least at the level of the previous year.
Strong growth in the pharmacy market
The pharmacies in the Galenica network further expanded their role as the first point of contact in the healthcare system. Galenica strengthened the pharmacy network in a targeted manner through acquisitions by a net 5 locations to 381 pharmacies (with Coop Vitality). Revenue in the “Pharmacies Omni-Channel” segment increased by 4.9% to CHF 1,473.3 million (excluding Coop Vitality). Adjusted for the expansion effect of 1.6%, the segment grew organically by 3.3%, which, taking the product mix into account, is slightly above market growth for stationary pharmacies (Rx and OTC products: 5.3%², non- medicine segment in the consumer healthcare market: -0.8%³).
The digital customer experience was consistently further developed. Both online sales and Click & Collect showed strong growth rates. At the same time, demand for consultations increased by almost 29%: 368,000 paid healthcare services were provided, including almost 93,000 vaccinations. In the reporting year, new cooperations were concluded with KPT and Helsana, which have integrated these services into selected insurance models since 1 January 2026 and reimburse patients accordingly.
“Products & Brands” grows in a challenging market environment
In the Swiss consumer healthcare market, Galenica was able to further strengthen its leading position with revenue growth of 6.2% to CHF 158.0 million. Revenue growth is supported by products from Cooper Consumer Health, for whose distribution Verfora has been responsible since 2025. Special effects in the previous year led to exceptionally high sales in Switzerland as well as in the export business. Accordingly, the export business declined in 2025 by -12.6% to CHF 36.2 million. Sales of Verfora products in the Swiss pharmacy and drugstore market decreased slightly by -0.6% due to weak demand for cold and pain remedies. Over the same period, the Swiss consumer healthcare market declined by -0.4%³, meaning that Galenica was slightly below market level due to the product mix.
Further expansion of the Galenica network
With the acquisition of Labor Team, Galenica was able to further develop its healthcare network in September and expand it with the “Diagnostics” segment. In 2025, Labor Team contributed revenue of CHF 40.7 million, accounting for around 1% of the Group’s revenue growth.
The “Services & Production” segment also developed positively and grew by 4%. All units – Bichsel, Lifestage and Medifilm – contributed to this growth. In the home care area, Galenica strengthened its position with a joint market presence of Bichsel and Lifestage Solutions. In addition, capacity at Medifilm was increased through a new blister packaging machine to meet rising demand.
Continuous growth in “Logistics & IT”
The “Logistics & IT” segment also developed favorably in 2025, achieving net revenue of CHF 3,332.6 million (+4.8%). In the “Wholesale” area, revenue growth of 4.8% to CHF 3,255.3 million was achieved. Development was at market level both in the physician segment, with growth of 3.9%, and in the pharmacy segment, with growth of 5.3%. Over the same period, the overall pharmaceutical market grew by 5.0%²; growth in the physician segment amounted to 3.9%², and growth in the stationary pharmacy segment to 5.3%².
Net revenue in the “Logistics & IT Services” area increased by 2.8% to CHF 79.6 million. HCI Solutions continues to make a major contribution to patient safety in Switzerland and recorded 553 million CDS checks (+50%) on the Documedis platform in the reporting year.
Net revenue January – December 2025 of the Galenica Group
(in CHF million) Dec 2025 Dec 2024 Change
Segment Products & Care 1,816.4 1,700.2 6.8%
Pharmacies Omni-Channel 1,473.3 1,404.3 4.9%
Products & Brands 194.2 190.2 2.1%
Services & Production 119.9 115.2 4.0%
Diagnostics 40.7 0
Segment Logistics & IT 3,332.6 3,180.5 4.8%
Wholesale 3,255.3 3,105.2 4.8%
Logistics & IT Services 79.6 77.5 2.8%
Corporate and eliminations -1,013.4 -959.6
Galenica Group 4,135.6 3,921.1 5.5%
New revenue presentation following the acquisition of Labor Team
Galenica has adjusted its revenue reporting in order to align reporting more closely with its strategic orientation and to further increase transparency. In the “Products & Care” segment, the “Diagnostics” area is now reported separately, while online and offline revenues are bundled under “Pharmacies Omni- Channel”. The “Services & Production” area now includes activities from Lifestage, Bichsel and Medifilm, and in the “Logistics & IT” segment, intra-group IT services are no longer reported. The prior-year figures have been adjusted accordingly.
¹ Excluding effects from IFRS 16 and IAS 19 as well as acquisition-related amortization from Labor Team.
Contact:
Iris Müller
Chief Communications Officer
media@galencia.com
--- END press release Galenica continues to grow: revenue rises to over CHF 4 billion ---
Marc Werner, CEO of Galenica, on the revenue figures: “Our broad positioning and the close interlinking within the network give us the necessary stability to continue growing and to help shape healthcare in Switzerland.” With this growth, Galenica clearly meets its stated revenue forecast. In addition, Galenica confirms the increased EBIT outlook announced in connection with the acquisition of Labor Team: for 2025, the Group expects an EBIT¹ increase of 10–12%. Galenica also continues to expect a dividend at least at the level of the previous year.
Strong growth in the pharmacy market
The pharmacies in the Galenica network further expanded their role as the first point of contact in the healthcare system. Galenica strengthened the pharmacy network in a targeted manner through acquisitions by a net 5 locations to 381 pharmacies (with Coop Vitality). Revenue in the “Pharmacies Omni-Channel” segment increased by 4.9% to CHF 1,473.3 million (excluding Coop Vitality). Adjusted for the expansion effect of 1.6%, the segment grew organically by 3.3%, which, taking the product mix into account, is slightly above market growth for stationary pharmacies (Rx and OTC products: 5.3%², non- medicine segment in the consumer healthcare market: -0.8%³).
The digital customer experience was consistently further developed. Both online sales and Click & Collect showed strong growth rates. At the same time, demand for consultations increased by almost 29%: 368,000 paid healthcare services were provided, including almost 93,000 vaccinations. In the reporting year, new cooperations were concluded with KPT and Helsana, which have integrated these services into selected insurance models since 1 January 2026 and reimburse patients accordingly.
“Products & Brands” grows in a challenging market environment
In the Swiss consumer healthcare market, Galenica was able to further strengthen its leading position with revenue growth of 6.2% to CHF 158.0 million. Revenue growth is supported by products from Cooper Consumer Health, for whose distribution Verfora has been responsible since 2025. Special effects in the previous year led to exceptionally high sales in Switzerland as well as in the export business. Accordingly, the export business declined in 2025 by -12.6% to CHF 36.2 million. Sales of Verfora products in the Swiss pharmacy and drugstore market decreased slightly by -0.6% due to weak demand for cold and pain remedies. Over the same period, the Swiss consumer healthcare market declined by -0.4%³, meaning that Galenica was slightly below market level due to the product mix.
Further expansion of the Galenica network
With the acquisition of Labor Team, Galenica was able to further develop its healthcare network in September and expand it with the “Diagnostics” segment. In 2025, Labor Team contributed revenue of CHF 40.7 million, accounting for around 1% of the Group’s revenue growth.
The “Services & Production” segment also developed positively and grew by 4%. All units – Bichsel, Lifestage and Medifilm – contributed to this growth. In the home care area, Galenica strengthened its position with a joint market presence of Bichsel and Lifestage Solutions. In addition, capacity at Medifilm was increased through a new blister packaging machine to meet rising demand.
Continuous growth in “Logistics & IT”
The “Logistics & IT” segment also developed favorably in 2025, achieving net revenue of CHF 3,332.6 million (+4.8%). In the “Wholesale” area, revenue growth of 4.8% to CHF 3,255.3 million was achieved. Development was at market level both in the physician segment, with growth of 3.9%, and in the pharmacy segment, with growth of 5.3%. Over the same period, the overall pharmaceutical market grew by 5.0%²; growth in the physician segment amounted to 3.9%², and growth in the stationary pharmacy segment to 5.3%².
Net revenue in the “Logistics & IT Services” area increased by 2.8% to CHF 79.6 million. HCI Solutions continues to make a major contribution to patient safety in Switzerland and recorded 553 million CDS checks (+50%) on the Documedis platform in the reporting year.
Net revenue January – December 2025 of the Galenica Group
(in CHF million) Dec 2025 Dec 2024 Change
Segment Products & Care 1,816.4 1,700.2 6.8%
Pharmacies Omni-Channel 1,473.3 1,404.3 4.9%
Products & Brands 194.2 190.2 2.1%
Services & Production 119.9 115.2 4.0%
Diagnostics 40.7 0
Segment Logistics & IT 3,332.6 3,180.5 4.8%
Wholesale 3,255.3 3,105.2 4.8%
Logistics & IT Services 79.6 77.5 2.8%
Corporate and eliminations -1,013.4 -959.6
Galenica Group 4,135.6 3,921.1 5.5%
New revenue presentation following the acquisition of Labor Team
Galenica has adjusted its revenue reporting in order to align reporting more closely with its strategic orientation and to further increase transparency. In the “Products & Care” segment, the “Diagnostics” area is now reported separately, while online and offline revenues are bundled under “Pharmacies Omni- Channel”. The “Services & Production” area now includes activities from Lifestage, Bichsel and Medifilm, and in the “Logistics & IT” segment, intra-group IT services are no longer reported. The prior-year figures have been adjusted accordingly.
¹ Excluding effects from IFRS 16 and IAS 19 as well as acquisition-related amortization from Labor Team.
Contact:
Iris Müller
Chief Communications Officer
media@galencia.com
--- END press release Galenica continues to grow: revenue rises to over CHF 4 billion ---
Editor's note: Image rights belong to the respective publisher.
Source:
More information and links:
Galenica AG
(company entry)
Galenica wächst weiter: Umsatz steigt auf über 4 Milliarden Franken (news article in german on swiss-press.com)
Galenica wächst weiter: Umsatz steigt auf über 4 Milliarden Franken (news article in german on swiss-press.com)
Official news partner:
TOP NEWS - powered by Help.ch
Pierangelo Campopiano becomes new Head of Sales AXA Versicherungen AG, 06.02.2026
Galenica continues to grow: revenue rises to over CHF 4 billion Galenica AG, 06.02.2026
FOUR PAWS Switzerland launches the campaign «Ready for a pet? Decide responsibly» VIER PFOTEN - Stiftung für Tierschutz, 19.01.2026
| NEWSTICKER - 06.02.2026 |
18:02 Uhr |
